Form 4: Cytek Biosciences Director Acquires Shares Through Routine RSU Vesting

Deborah J. Neff, a Director at Cytek Biosciences, Inc., acquired 15,706 shares of common stock on June 5, 2025, through the vesting of Restricted Stock Units.

Summary

• Deborah J. Neff, a Director of Cytek Biosciences, Inc. (CTKB), reported a transaction on June 5, 2025.
• The transaction involved the vesting of 15,706 Restricted Stock Units (RSUs).
• Each RSU represented a contingent right to receive one share of the Issuer's common stock.
• 100% of the shares subject to the RSU Award vested on June 5, 2025.
• As a result of the vesting, Ms. Neff acquired 15,706 shares of Cytek Biosciences, Inc. Common Stock.
• The acquisition price for the common stock upon RSU conversion was $0.
• Following this transaction, Ms. Neff beneficially owns 15,706 shares of Common Stock directly.

Sentiment

Score: 7

Explanation: The transaction represents a routine vesting of Restricted Stock Units, increasing a director's direct ownership in the company, which is generally viewed as a positive alignment of interests with shareholders.

Positives

• The acquisition of 15,706 shares of common stock by Director Deborah J. Neff through RSU vesting increases her direct ownership in Cytek Biosciences, aligning her interests more closely with shareholders.

Negatives

• No direct negative implications are apparent from this routine insider transaction filing.

Risks

• This document, a Form 4, primarily reports an insider transaction and does not detail specific company risks.

Future Outlook

This Form 4 filing is a historical report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• This Form 4 filing does not include notable quotes or paraphrased statements from company management.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Comparison to Industry Standards

• This document reports a standard insider transaction (RSU vesting) and does not contain information suitable for comparison to industry-wide financial or operational benchmarks.

Related Party Transactions

• The reported transaction is a compensation-related event (vesting of Restricted Stock Units) involving a director, which is a common form of related-party transaction in executive compensation.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director may signal confidence and better alignment of interests.
• Employees: No direct impact on general employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• This Form 4 filing reports a completed transaction and does not outline specific future actions or milestones for the company or the reporting person.

Key Dates

Recommendation

Keywords

Cytek Biosciences, CTKB, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Common Stock, Director Ownership, Deborah J Neff